Baker Bros. Advisors LP 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-08-17 5:12 pm Sale | 2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 473,605 19.990% | -28,549 (-5.69%) | Filing |
| 2023-07-19 5:28 pm Purchase | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 502,154 19.990% | 290,663 (+137.43%) | Filing |
| 2020-12-23 5:11 pm Purchase | 2020-07-07 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 211,491 9.990% | 21,241 (+11.16%) | Filing |